Washington University School of Medicine

Digital Commons@Becker
HRPO Publications

Human Research Protection Office

2013

Washington University in St. Louis research toolkit for medical
student researchers
Human Research Protection Office, Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/hrpopubs

Recommended Citation
Human Research Protection Office, Washington University School of Medicine in St. Louis, "Washington
University in St. Louis research toolkit for medical student researchers" (2013). HRPO Publications. Paper
6.
https://digitalcommons.wustl.edu/hrpopubs/6

This Other is brought to you for free and open access by the Human Research Protection Office at Digital
Commons@Becker. It has been accepted for inclusion in HRPO Publications by an authorized administrator of
Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Research Toolkit
For Medical Student Researchers
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This Research Toolkit is a guide for conducting
research as a Medical Student at the Washington
University in St. Louis School of Medicine. It contains
information about important points of federal and
institutional policy related to research, as well as
helpful resources available to the WU research
community.
For a Medical Student Researcher that intends to
develop a research protocol that involves human
subjects, review and approval by the Institutional
Review Board (IRB) is required. Students conducting
independent research should complete CITI training
and refer to the Human Research Protection Office
(HRPO) for help in beginning the application process.
Medical Student Researchers may also become a study
team member of an existing project. All student
researchers participating in existing projects will need
to complete Human Subjects Training (CITI) and be
added to the approved study.
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Washington University in St. Louis
Human Research Protec on Oﬃce
2013
—
All original materials in this document are protected by a
Crea ve Commons license. Materials may be used with
permission and a ribu on.

At any me during the research process, one of the most helpful resources available to you is the
HRPO SWAT! (Staﬀ With Answers Today!) service. There is a HRPO staﬀ member On Call at all
mes during business hours. Just call 314‐633‐7400 to be connected.
In addi on, there are Oﬃce Hours available throughout the week. Check the HRPO website for the
current Oﬃce Hours schedule.
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RESEARCH
The DHHS regulatory defini on of research is outlined at the beginning of the “Common Rule” (45
CFR 46.102). This defini on applies to all research ac vi es conducted at Washington University in
St. Louis. In this sec on of the DHHS regula ons, a basic dis nc on between research and human
subjects research is defined as following:
Research is “A systema c inves ga on including research development, tes ng and evalua on,
designed to develop or contribute to generalizable knowledge.”


It is systema c in that it involves: A predetermined method for answering specific
ques ons or achieving specified outcomes that has taken into account various
factors that could aﬀect data collected during the study.



It is generalizable because it involves: An intent to contribute to your field of
study by producing results that can be applied beyond the ini al par cipant
popula on.

Human Subjects Research is research that involves “a living individual about whom an
inves gator conduc ng research obtains: (1) data through interven on or interac on with the
individual; or (2) iden fiable private informa on.”
Let’s take a closer look at this:


About whom = a living human subject about whom data are being collected.



Interven on or Interac on = “both physical procedures by which data are gathered
(for example, venipuncture) and manipula ons of the subject or the subject's
environment that are performed for research purposes. Interac on includes
communica on or interpersonal contact between inves gator and subject.”



Iden fiable Private Informa on = “informa on about behavior that occurs in a
context in which an individual can reasonably expect that no observa on or
recording is taking place, and informa on which has been provided for specific
purposes by an individual and which the individual can reasonably expect will not
be made public. Private informa on must be individually iden fiable in order for
obtaining the informa on to cons tute research involving human subjects.”
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RESEARCH
The FDA regulatory defini on of research is slightly diﬀerent, given that the FDA has specific
jurisdic on over research that involves drugs, biologics, devices, and related test ar cles (21 CFR
50.3). This defini on also applies to all research ac vi es involving FDA‐regulated test ar cles
conducted at Washington University in St. Louis. In this sec on of the FDA regula ons, “research” is
defined in terms of “clinical inves ga on”:
A Clinical Inves ga on is:
“Any experiment that involves a test ar cle and one or more human subjects that is either
subject to requirements for prior submission to the Food and Drug Administra on under
sec on 505(i), or 520(g) of the act, or is not subject to requirements for prior submission to
the Food and Drug Administra on under these sec ons of the act, but the results of which
are intended to be submi ed to, or held for inspec on by the Food and Drug
Administra on as part of an applica on for a research or marke ng permit.” (21 CFR 50.3
(c))
A Human Subject is:
“an individual who is or becomes a par cipant in research, either as a recipient of the test
ar cle or as a control. A subject may be either a healthy human or a pa ent.” (21 CFR 50.3
(g))
A Test Ar cle is:
“any drug (including a biological product for human use), medical device for human use,
human food addi ve, color addi ve, electronic product, or any other ar cle subject to
regula on under the act or under sec ons 351 and 354‐360F of the Public Health Service
Act (42 U.S.C. 262 and 263b‐263n).” (21 CFR 50.3(j))
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RESEARCH
Understanding the nuances of these defini ons is important, because according to federal and
ins tu onal policy, human subjects research requires review and approval by an Ins tu onal
Review Board before implementa on.

How to determine if your research involves human subjects:
At WU, inves gators are expected to recognize when they are engaged in ac vi es subject
to IRB jurisdic on. Contact the Human Research Protec on Oﬃce (314‐633‐7400) and a
staﬀ member will guide you through the process of making this determina on. But before
making this decision yourself, it is helpful to consult with the IRB. There are many ethical
and regulatory factors that may make your proposed research subject to review.

Examples of Non‐Human Subjects Research:


Procedures performed for clinical purposes.



Case histories or series (if a limited number of pa ents are included, typically five
or less). There may by important HIPAA issues to consider even if the case series
does not qualify as Human Subjects Research.



Review and analysis of publically available data.



Research that involves cadavers.

Examples of Human Subjects Research:


Conduc ng a chart review of treatment outcomes.



Surveying cancer survivors about percep ons of quality of care.



Collec ng ssue or blood for analysis.



Compara ve study of clinical interven ons.

6

RESEARCH
Given these regulatory defini ons of research and human subjects, these are the Basic
Requirements for Research at WU:


Any research that involves human subjects conducted by a WU/BJH/SLCH
employee, agent, student, fellow, or post‐doctoral appointee must be reviewed
and approved by the IRB before any proposed study procedures begin.



In addi on to the regula ons for the protec on of human subjects in research,
inves gators are required to follow all relevant federal, state, and ins tu onal
policy relevant to their research.



Any changes to approved research must be reviewed and approved by the IRB
before proposed changes to research is implemented.



Any adverse events or unan cipated problems must be reported appropriately to
the IRB, according to federal and ins tu onal policy.



Any devia ons from the study procedures approved by the IRB must be reported
appropriately to the IRB, according to federal and ins tu onal policy.

—

Research Misconduct:
Washington University defines research misconduct as:
1. Fabrica on, falsifica on, or plagiarism in proposing, performing, or reviewing research, or in
repor ng research results; or
2. Knowing viola ons of federal and ins tu onal rules and regula ons governing the conduct of
research involving human research par cipants that are serious or con nuing; or
3. Viola ons of the University's Policy for Authorship on Scien fic and Scholarly Publica ons.
Research misconduct does not include honest error or diﬀerences of opinion or diﬀerences in
interpreta ons of data. A finding of research misconduct requires that: There be a significant
departure from the accepted prac ces of the relevant research community; and the research
misconduct be commi ed inten onally, knowingly, or recklessly; and the allega on be proven by a
preponderance of evidence.
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INSTITUTIONAL REVIEW BOARD

In 1972, several journalists broke the story that scien sts conduc ng a federally funded study in
Tuskegee, Alabama had been withholding penicillin from hundreds of male subjects with syphilis
since the late 1940s in order to observe the natural history of the disease. A er being told they
were simply being treated for “bad blood,” subjects also received spinal taps for research purposes
that were described as a “special free treatment.” 28 par cipants died from lack of treatment.
Whistleblower accounts of the infamous Tuskegee Experiment generated enough public outrage
that Congress was moved to pass the Na onal Research Act in 1974.
Now mandated by the 1974 Act, any federally funded research that involves human par cipants
requires review by commi ees we call Ins tu onal Review Boards (IRBs), which apply a specific set
of regula ons designed to protect the safety and welfare of human research par cipants. IRBs use
these regula ons to evaluate the risks and benefits of proposed research, ensure the equitable
selec on of subjects, ensure that par cipants will be adequately informed about the nature of the
research, and address related concerns.
In 1974, an ini al set of regula ons for the protec on of human subjects were registered (45 CFR
46). Several years later, the Belmont Report was produced by a commissioned panel of experts and
established respect for persons, beneficence, and jus ce as the cornerstone principles of human
research ethics (see the follow page for a summary of this document). 45 CFR 46 was subsequently
revised, and regula ons specific to pregnant women and neonates, prisoners, and children were
added.

In a watershed 1966 NEJM ar cle surveying the conduct of 50 published studies,
Henry K. Beecher noted many research ethical failures:
“Evidence is at hand that many of the pa ents in the examples to follow never had
the risks sa sfactorily explained to them, and it seems obvious that hundreds have
not known that they were the subjects of an experiment although grave
consequences have been suﬀered as a direct result of experiments described
here.” (Ethics and clinical research. NEJM, 1966, 274: 1354–1360.)
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INSTITUTIONAL REVIEW BOARD

From The Belmont Report (1979)
“The dis nc on between research and prac ce is blurred partly because both o en occur together (as
in research designed to evaluate a therapy) and partly because notable departures from standard
prac ce are o en called “experimental” when the terms “experimental” and “research” are not
carefully defined.”
“For the most part, the term “prac ce” refers to interven ons that are designed solely to enhance
the well‐being of an individual pa ent or client and that have a reasonable expecta on of success…
By contrast, the term ”research” designates an ac vity designed to test an hypothesis, permit
conclusions to be drawn, and thereby to develop or contribute to generalizable knowledge
(expressed, for example, in theories, principles, and statements of rela onships).”

Belmont’s Basic Ethical Principles:






Respect for Persons. Respect for persons incorporates at least two ethical convic ons:


Individuals should be treated as autonomous agents. There is an ethical requirement to
acknowledge autonomy.



Persons with diminished autonomy are en tled to protec on. There is an ethical
requirement to protect those with diminished autonomy.

Beneficence. Persons are treated in an ethical manner not only by respec ng their decisions
and protec ng them from harm, but also by making eﬀorts to secure their well‐being. Two
general rules have been formulated as complementary expressions of beneficent ac ons in this
sense:


Do not harm.



The research process must maximize possible benefits and minimize possible harms.

Jus ce. Who ought to receive the benefits of research and bear its burdens? This is a ques on
of jus ce, in the sense of “fairness in distribu on” or “what is deserved.” An injus ce occurs
when some benefit to which a person is en tled is denied without good reason or when some
burden is imposed unduly.
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What is an IRB?
An IRB is a commi ee of at least five members with diverse backgrounds that have exper se to
review the type of research being proposed. These commi ees require:


At least one member whose primary background is related to science/medicine.



At least one member whose primary background is not related to science/
medicine.



At least one member not aﬃliated with the ins tu on conduc ng the research.

What does an IRB do?
The IRB meets on a regular basis to review proposed human subjects research based on the criteria
for approvability found in the federal regula ons (see below for these criteria). The IRB approves
research, recommends changes to the research that will be er protect the rights and welfare of
human subjects, or disapproves research.
IRB review is required:


Prior to the conduct of research.



Any me there is a change to the research.



Any me there has been an event that may increase risk to par cipants or others.



At least every 12 months on a con nuing cycle.

“The mission of the IRB is to protect the rights and welfare of par cipants in ‘human
research’ as defined in 45 CFR 46.102(d) and (f) and ‘clinical inves ga ons’ as
defined in 21 CFR 50.3(c).“
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Criteria for the Approvability of Research (45 CFR 46.111/21 CFR 56.111)
In order to approve research covered by this policy the IRB shall determine that all of the following
requirements are sa sfied:
(1) Risks to subjects are minimized:
(i) By using procedures which are consistent with sound research design and which do not
unnecessarily expose subjects to risk, and
(ii) whenever appropriate, by using procedures already being performed on the subjects for
diagnos c or treatment purposes.
(2) Risks to subjects are reasonable in rela on to an cipated benefits, if any, to subjects, and the
importance of the knowledge that may reasonably be expected to result.
In evalua ng risks and benefits, the IRB should consider only those risks and benefits that may
result from the research (as dis nguished from risks and benefits of therapies subjects would
receive even if not par cipa ng in the research).
The IRB should not consider possible long‐range eﬀects of applying knowledge gained in the
research (for example, the possible eﬀects of the research on public policy) as among those
research risks that fall within the purview of its responsibility.
(3) Selec on of subjects is equitable.
In making this assessment the IRB should take into account the purposes of the research and
the se ng in which the research will be conducted and should be par cularly cognizant of the
special problems of research involving vulnerable popula ons, such as children, prisoners,
pregnant women, mentally disabled persons, or economically or educa onally disadvantaged
persons.
(4) Informed consent will be sought from each prospec ve subject or the subject's legally
authorized representa ve, in accordance with, and to the extent required by §46.116 (See Consent
Elements).
(5) Informed consent will be appropriately documented, in accordance with, and to the extent
required by §46.117.
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(6) When appropriate, the research plan makes adequate provision for monitoring the data
collected to ensure the safety of subjects.
(7) When appropriate, there are adequate provisions to protect the privacy of subjects and to
maintain the confiden ality of data.
When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as
children, prisoners, pregnant women, mentally disabled persons, or economically or educa onally
disadvantaged persons, addi onal safeguards have been included in the study to protect the rights
and welfare of these subjects.

—

This last point addresses what IRBs refer to as “vulnerable popula ons.” The regula ons contains
specific policy for the following three:
· Pregnant Women, Human Fetuses and Neonates
Research involving pregnant women and fetuses may only be approvable if it meets a lengthy list of
condi ons described in the regula ons. For research that holds out the prospect of direct benefit
solely to the fetus, the consent of the pregnant woman and the father is required. For other types
of research, the consent of the pregnant woman is o en suﬃcient.
· Prisoners
Prisoners are considered vulnerable due to being in an environment that can inhibit free choice.
Research involving prisoners may only be allowed in four categories described in the regula ons. An
IRB prisoner representa ve is required for the review of these studies.
· Children (Minors)
The regula ons define children as par cipants that have not reached the legal age to consent to
treatments or procedures involved in the research. The regula ons define four categories of
research for children, generally dis nguished by the risks and benefits of proposed research. Each
category has specific assent and consent requirements that are evaluated during IRB review.
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Types of IRB Review
DHHS regula ons describe several diﬀerent ways proposed Human Subjects Research is reviewed
by the IRB (FDA regula ons contain addi onal guidance for the review of clinical inves ga ons that
involve test ar cles. The IRB first makes a basic determina on about whether a study qualifies as
human subjects research or non‐human subjects research. If a proposed study crosses the
threshold defined by both “research” and “human subject,” the following required review can go
several direc ons:


Exempt: There are a number of categories of research described in the regula ons
that are considered exempt from con nuing IRB review.
Some chart reviews or surveys, for example, can fall into an exempt category. These
applica ons are not as intensive as other types of review.



Expedited Review: If a study does not meet the condi ons of an exempt category, it
may fall under one of the categories that qualify research for expedited review. This
means that a study will be reviewed by one IRB reviewer rather than being submi ed
for review at a fully convened IRB mee ng. Such studies must pose no more than
minimal risks to subjects, which according to the regula ons means that the
“probability and magnitude of harm or discomfort an cipated in the research are not
greater in and of themselves than those ordinarily encountered in daily life or during
the performance of rou ne physical examina ons or tests.”
Iden fiable surveys and some collec ons of blood are examples of research that
require expedited review.



Full Board Review: Studies that do not meet either exempt or expedited condi ons
require review at a fully convened IRB mee ng. Typically, this applies to studies that
involve greater than minimal risk to subjects.
Clinical trials and are examples of research that requires full board review.
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Submi ng to the IRB
To submit an applica on to the WU IRB, you will need to pick the right applica on in myIRB. One of
the very first ques ons in a new applica on form asks if you want “Regular” or “Exempt Status”
review. If you think your study qualifies for exempt status, selec ng that op on will open up an
abbreviated applica on. If your study may be either expedited or full board, selec ng “regular”
here will open up the full applica on.
Other applica on types include:


Modifica on/Update Form: This applica on allows you to submit modifica ons or
changes to research to the IRB for review.



Con nuing Review Form: An approved study must submit a con nuing review
applica on at least every 12 months. There are rare occasions in which the IRB
may require a shorter con nuing review cycle.



Reportable Event Form: This applica on allows you to submit reports of
unan cipated problems and issues related to non‐compliance to the IRB for
review.



Excep on Request Form: This applica on allows you to submit a request for an
excep on from an approved protocol for one research subject to the IRB for
review.



Project Close Form: This applica on allows you to no fy the IRB that a study has
been concluded.

If you intend to manage the myIRB applica on for your own study, you can save
yourself a lot of me by a ending the myIRB training sessions. One two‐hour
session covers the basics of the myIRB system and New Project applica ons.
Addi onal sessions cover other training topics. You can sign up for these training
sessions at: hrpohome.wustl.edu.
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GETTING STARTED

During the ini al stages of any research project, there are a number of basic ques ons that need to
be addressed. Fortunately, the regula ons are helpful in that they help narrow the focus of these
ques ons in such a way that thinking from the perspec ve of IRB review can make your protocol
development and review melines more eﬃcient. In addi on, thinking about some of these
ques ons during the planning stages can lead to more robust and ethical research prac ces.

Some important ques ons to consider:


What is your research ques on?
The ethical conduct of research is something that begins with the design of your study. Are
all of your proposed procedures relevant to the research? If not, then pu ng par cipants
at any addi onal risk related to study procedures is ethically problema c. Is your
popula on size large enough to produce the necessary data to fulfill intended outcomes? If
not, then you should consider a diﬀerent study design or consider alterna ve data
collec on and analyses strategies. These kinds of design‐oriented ques ons should be
considered even while the ideas for your research are s ll developing.



What risks are there?
When evalua ng the risks related to your study, the IRB considers all procedures defined in
the protocol, subject vulnerabili es, privacy and confiden ality issues, and a range of
reasonably poten al risks that the inves gator needs to address. What can you do to
minimize any risk related to your study?



Do benefits outweigh risks?
Many ethical problems inherent to research‐related risk are evaluated rela ve to the
possibility that a study poses direct benefit to subjects or more general benefit to society
and the advancement of knowledge in a par cular area. When considering the par cipa on
of vulnerable popula ons such as children or pregnant women, the regula ons contain
specific requirements for evalua ng the risks versus poten al benefit. This evalua on also
guides what type of consent process will need to take place while recrui ng par cipants.
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How are you going to recruit subjects?
The selec on of subjects for research is an important issue from the perspec ve of research
design, but it is also an important element of the ethical and regulatory implica ons of your
study. If your plan is only based on convenience, it may not be approved by the IRB.
Recrui ng subjects that may best benefit from research may be more diﬃcult in terms of
recruitment and reten on, but both the risks and benefits of research should be
fairly distributed across your poten al pool of subjects.



How will you obtain and document informed consent?
You should begin developing your plan to obtain and document informed consent in the
earliest stages of project development. If you think a waiver of informed consent may be
necessary for your research, consult as early as possible with HRPO about the regulatory
considera ons involved. If you are working with vulnerable popula ons, there may be
addi onal consent and consent documenta on concerns that are also best nego ated in
consulta on with HRPO. While dra ing your consent form, be sure to think about scien fic
language and concepts from the perspec ve of your poten al subjects, and write in such a
way that will be easily understood by a layperson.



What data and safety monitoring will be necessary for your study?
Studies that pose risk to subjects o en require an addi onal plan to regularly monitor data
produced by the study and the overall safety of subjects during the study. Many data and
safety monitoring plans include physicians or scien sts that are not engaged in the research
to lend a measure of independent review to the oversight process.



What privacy and confiden ality protec ons need to be in place?
Privacy refers to an individual’s control over the ming and context of sharing personal
informa on. Confiden ality refers to an inves gator’s control over the sharing or release of
private informa on about a research subject. Many studies collect informa on about
par cipants that may cause harm if released. In such cases, protec ng the privacy and
confiden ality of par cipants is a significant concern. Private informa on should not be
collected unless it is needed to answer your study ques on.
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But even in studies collec ng more general informa on, the collec on of informa on about
subjects for research purposes requires detailed a en on to the physical or electronic
protec ons in place during the collec on and storage process.


Are your recrui ng any vulnerable popula ons?
There may be cases when a study requires the par cipa on of vulnerable popula ons to
answer the research ques on. In other cases, a large sample size may naturally contain
poten al subjects that have vulnerabili es. Either way, the recruitment of vulnerable
popula ons can require addi onal ethical, regulatory, and administra ve scru ny. When
considering poten al subjects, keep in mind that the regulatory categories of pregnant
women and neonates, prisoners, and children represent important forms of vulnerability.
But many more hidden vulnerabili es include: terminal illness, economic disadvantage, non
‐English speaking, decisional impairment, etc...

There are two ways to enhance your recruitment strategies at WU:


Volunteers For Health is a Research Par cipant Registry that can help
researchers find qualified study par cipants.



The Center for Community‐Engaged Research (CCER) in the ICTS can connect
researchers with HealthStreet, which aids in the recruitment of local
community members.
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What Should I Keep In Mind While Ge ng Started?



Before you begin developing a protocol and filling out a myIRB applica on, it is o en helpful to
talk to someone in the Human Research Protec on Oﬃce to see if there are and specific
regulatory or ethical issues you should consider along the way. This can save you a lot of me
during the review process.



The earlier you get started with pu ng together a protocol and myIRB applica on, the be er.
The ini al and ongoing administra on of your study can o en require more me than you
an cipate, and this addi onal me should be factored into your schedule.



In addi on to the me it takes to submit your study to the IRB, your study may also be subject
to review by addi onal review commi ees at WU. If your study is subject to addi onal review,
this may increase your an cipated me to approval. (See below for a descrip on of other
review commi ees at WU.)



Be aware of your resources. The Human Research Protec on Oﬃce is a good place to turn if
you are not sure who to talk to about an issue with your study or are looking for addi onal local
or na onal resources.



Research seldom goes as planned. Become familiar with what kinds of events need to be
reported and how to get approval for modifica ons to your research. If you are unsure about an
event or change in ques on, a consult with HRPO can quickly clarify what you need to do next
when encountering unan cipated problems.
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And Also… Avoid The Common Mistakes:


Take CITI training and set up a myIRB profile as soon as possible: myIRB.wusm.wustl.edu. Also
complete your compliance profile to see what addi onal training requirements may be
necessary for your proposed research. This profile can be accessed at:
complianceprofile.wustl.edu/



Be aware of IRB review melines and related ins tu onal review scheduling issues. Given the
set of deadlines associated with Medical Student research at WU, this is an important
considera on.



Consult with HRPO to see if your study involves an inves ga onal drug or device, and is
therefore also subject to FDA regula ons. This would include, for example, the use of assays or
in vitro devices in studies involving collected ssue or the tes ng of new so ware algorithms in
hearing devices.



Recognize subject vulnerabili es. While the IRB is charged with evalua ng regula on‐defined
vulnerabili es, addi onal hidden vulnerabili es are also o en discovered during the review
process.



Write consent/assent documents that are not too technical for poten al subjects.



Include all relevant parts of the myIRB consent form template while dra ing your consent and/
or assent documents.



Be sure to include language in your consent/assent documents that adequately describes
gene c and genomic research to poten al subjects, which includes a descrip on of privacy
risks.



Know the diﬀerence between “coded” with “anonymized.” Coded data are data that are
collected with iden fiers, but the data have been coded or keyed in such a way that only the
person storing the code can re‐iden fy data sets or entries. Anonymized data are data that have
been permanently stripped of iden fiers such that no one can relink to iden fiers. The
regulatory diﬀerence between these two methods of collec ng and storing data can be
significant.



Talk with HRPO about addi onal concerns related to research that involves interna onal
subjects or research sites.
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Other WU Review Commi ees:
There are a number of commi ees at Washington University that review human subjects research
prior to or during review by the IRB. Several of these commi ees must give their approval before
the IRB can begin to review the research. Consult with HRPO if you think one or more of these
commi ees may be relevant to your research:



ICOI (Ins tu onal Conflict of Interest Review Commi ee)



CIRC (Conflict of Interest Review Commi ee)



ESCRO (Embryonic Stem Cell Research Oversight Commi ee)



IBC (Ins tu onal Biosafety Commi ee)



P&T (Pharmacy and Therapeu cs Commi ee)



PRMC (Protocol Review and Monitoring Commi ee)



RDRC (Radioac ve Drug Research Commi ee)



RSC (Radia on Safety Commi ee)
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One of the most diﬃcult aspects of naviga ng your first few research projects is knowing where to
go to complete required training or get advice about an aspect of your research. Washington
University in St. Louis has a very ac ve culture of resources for inves gators. Your capacity for
comple ng a valuable study can expand greatly by taking advantage of these resources. Some of
these resources lead to places where you can receive required training.
Required


Human Subjects Training (CITI): CITI is a web based human research protec ons training
program created by the Collabora ve Ins tu onal Training Ini a ve. Individuals aﬃliated with
Washington University can access the program through RAS (Research Administra on System)
to complete their Human Subjects training. You will not be able to submit a myIRB applica on
or become a study team member on an exis ng study un l this training is completed. Call the
HRPO oﬃce for more details (314‐633‐7400). CITI training is accessed through the HRPO
website: hrpohome.wustl.edu



HIPAA Training: HIPAA training is required for anyone that has access to Protected Health
Informa on (PHI) at WU. Contact the WU HIPAA Oﬃce for more details (314‐747‐4975).



Research‐Specific Training: Working in the laboratory se ng, with lasers, magne c fields,
pa ent care, radioac ve materials, recombinant DNA, or some biological toxins requires
specific training that can be accessed here: complianceguide.wustl.edu

At any me during the research process, one of the most helpful resources available to you is the
HRPO SWAT! (Staﬀ With Answers Today!) service. There is a HRPO staﬀ member On Call at all
mes during business hours. Just call 314‐633‐7400 to be connected.
In addi on, there are Oﬃce Hours available Tues. 1‐4 and Fri. 8‐11 in a convenient loca on. HRPO
staﬀ can work on applica ons with you in real me, work through pre‐submission ques ons with
you on the spot, and provide a range of services. Visit the HRPO website or call 314‐633‐7400 for
loca on informa on.
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Helpful Administra ve Resources


RCR Resources: Resources for comple ng Responsible Conduct of Research requirements can
be accessed here: research.wustl.edu/ComplianceAreas/rcr/Pages/default.aspx



Proposal/Grant Development: A very helpful resource for grant‐wri ng can be found in the
Proposal Development Toolkit, accessible at: proposalhelp.wustl.edu



WUSTL Research Policy/Guidelines: A comprehensive list of research guidelines and policies can
be found at: research.wustl.edu. You can complete a helpful Compliance Profile at:
complianceprofile.wustl.edu



Allscripts Training: Ask your department for Allscripts View Only access. Allscripts help‐desk can
be contacted at 314‐935‐0909.



ClinDesk Training: For access to ClinDesk contact the Oﬃce for Medical Student Research (314‐
362‐6857) or email Roz Robinson with your phone number and research department
(robinsonr@wusm.wustl.edu). ClinDesk support can be contacted at 314‐362‐4700.



myIRB Training and Profile: myIRB training is a very helpful way to get your feet wet in the IRB
applica on process. You can sign up for sessions and a profile at: hrpohome.wustl.edu.

Helpful Research Resources


Becker Medical Library ‐ Research and Publishing Support: Staﬀ at Becker can conduct literature
searches and provide support for a wide range of research and publica on issues. All Becker
resources are accessible at: becker.wustl.edu



PubMed and Endnote Training: Staﬀ at Becker frequently hold training sessions on using
PubMed and Endnote during your research. All Becker resources are accessible at:
becker.wustl.edu



Becker Medical Library ‐ Bioinforma cs: Staﬀ at Becker can assist with database queries and
help you find the right tools for your research. All Becker resources are accessible at:
becker.wustl.edu



ICTS Resources: The ICTS has a number of cores that provide valuable support during the
research process. These resources range from regulatory support to research design. All ICTS
resources are accessible at: icts.wustl.edu/cores
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ICTS Tissue Banking: The ICTS Transla onal Pathology & Molecular Phenotyping Core provides
assistance for inves gators with ssue banking needs. All ICTS resources are accessible at:
icts.wustl.edu/cores



IT Security: Many types research require compliance with WU IT security and encryp on policy.
The Security and Privacy Oﬃce can help you navigate that process at: secpriv.wusm.wustl.edu



Clinical Research Forms Library: The Oﬃce for the Vice Chancellor of Research website
maintains a Library of case report forms, data collec on forms, delega on logs, and a variety of
administra ve tools helpful during the research process.



Community‐Based Par cipatory Research: HRPO has produced a number of helpful materials on
developing research that is Community‐Based or Community‐Engaged. These materials can be
accessed at: digitalcommons.wustl.edu/hrpo



Volunteers For Health: Volunteers for Health is a Research Par cipant Registry that can help
connect researchers with poten al subjects: v .wustl.edu



Center for Community‐Engaged Research / HealthStreet: The CCER helps researchers develop
community‐engaged research. HealthStreet serves as the local community par cipant
recruitment component of this process. h p://icts.wustl.edu/cores/community.aspx

Helpful Federal Resources


45 CFR 46 (Common Rule): h p://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html



Presiden al Bioethics Commissions: bioethics.gov



Oﬃce of Human Research Protec ons: h p://www.hhs.gov/ohrp/



Food and Drug Administra on ‐ Clinical Trials Guidance / Good Clinical Prac ce: h p://
www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/default.htm



HIPAA: h p://www.hhs.gov/ocr/privacy/index.html



Gene c/Genomic Research: h p://www.genome.gov/



Transna onal Research Regula ons: h p://www.hhs.gov/ohrp/interna onal/
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Medical Student Research Checklist
Page Numbers Correspond to Medical Student Researcher Toolkit. The below may not
be comprehensive in all cases, and is only intended as general guidance.

If Par cipa ng in a Current Study

If Conduc ng Independent Study

Consult with Research Faculty Mentor

Consult with Research Faculty Mentor
Begin Developing Research Plan (18‐19)

Required:
Complete HIPAA Training (21)

Required:

Complete CITI Training (21)

Complete HIPAA Training (21)

Create myIRB Profile (22)

Complete CITI Training (21)

Be added to Study as a “Research Team
Member” through a Modifica on.

Create myIRB Profile (22)

Very Helpful:
Complete myIRB Training (22)
Create Compliance Profile (22)
Addi onal Training as Needed:

Complete myIRB Applica on
Very Helpful:
Complete myIRB Training (22)
Create Compliance Profile (22)
Consult with HRPO via Oﬃce Hours prior to
myIRB applica on (21)

Allscripts Training (22)
ClinDesk Training (22)

Addi onal Training as Needed:

Research‐Specific Training (21)

Allscripts Training (22)

CITRIX / VPN Training

ClinDesk Training (22)
Research‐Specific Training (21)
CITRIX / VPN Training
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